Last reviewed 2026-04-22 · How we verify

ceftriaxone/oxacillin

ceftriaxone/oxacillin is a Beta-lactam antibiotic combination Small molecule drug developed by UPECLIN HC FM Botucatu Unesp. It is currently FDA-approved for Serious bacterial infections including meningitis, endocarditis, and sepsis, Hospital-acquired and community-acquired infections with mixed gram-positive and gram-negative pathogens.

This combination of two beta-lactam antibiotics inhibits bacterial cell wall synthesis through inhibition of penicillin-binding proteins, providing broad-spectrum coverage against gram-positive and gram-negative bacteria.

This combination of two beta-lactam antibiotics inhibits bacterial cell wall synthesis through inhibition of penicillin-binding proteins, providing broad-spectrum coverage against gram-positive and gram-negative bacteria. Used for Serious bacterial infections including meningitis, endocarditis, and sepsis, Hospital-acquired and community-acquired infections with mixed gram-positive and gram-negative pathogens.

At a glance

Mechanism of action

Ceftriaxone is a third-generation cephalosporin that inhibits cross-linking of peptidoglycan in bacterial cell walls. Oxacillin is a beta-lactamase-resistant penicillin effective against staphylococci. Together, they provide synergistic coverage against a wide range of aerobic and anaerobic bacteria, particularly useful in serious infections where broad coverage is needed.

Approved indications

• Serious bacterial infections including meningitis, endocarditis, and sepsis
• Hospital-acquired and community-acquired infections with mixed gram-positive and gram-negative pathogens

Common side effects

• Diarrhea
• Nausea and vomiting
• Rash
• Hypersensitivity reactions
• Phlebitis at injection site

Key clinical trials

• Oral-only Antibiotics for Bone and Joint Infections in Children (PHASE4)
• Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections (NA)
• Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens (PHASE1)
• Gentamicin in Cardiac Surgery (NA)
• Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) (PHASE4)
• Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital (NA)
• Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
• Ceftriaxone as Home IV for Staph Infections (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ceftriaxone/oxacillin CI brief — competitive landscape report
• ceftriaxone/oxacillin updates RSS · CI watch RSS
• UPECLIN HC FM Botucatu Unesp portfolio CI

Frequently asked questions about ceftriaxone/oxacillin

Related

• Drug class: All Beta-lactam antibiotic combination drugs
• Target: All drugs targeting Penicillin-binding proteins (PBPs)
• Manufacturer: UPECLIN HC FM Botucatu Unesp — full pipeline
• Therapeutic area: All drugs in Infectious Disease
• Indication: Drugs for Serious bacterial infections including meningitis, endocarditis, and sepsis
• Indication: Drugs for Hospital-acquired and community-acquired infections with mixed gram-positive and gram-negative pathogens

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing